[1] |
ISON MG, NALESNIK MA. An update on donor-derived disease transmission in organ transplantation[J]. Am J Transplant, 2011, 11(6):1123-1130. DOI: 10.1111/j.1600-6143.2011.03493.x.
|
[2] |
DESAI R, COLLETT D, WATSON CJ, et al. Cancer transmission from organ donors-unavoidable but low risk[J]. Transplantation, 2012, 94(12):1200-1207. DOI: 10.1097/TP.0b013e318272df41.
|
[3] |
NALESNIK MA, WOODLE ES, DIMAIO JM, et al. Donor‐transmitted malignancies in organ transplantation: assessment of clinical risk[J]. Am J Transplant, 2011, 11(6): 1140-1147. DOI: 10.1111/j.1600-6143.2011.03565.x.
|
[4] |
GREEN M, COVINGTON S, TARANTO S, et al. Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee[J]. Transplantation, 2015, 99(2): 282-287. DOI: 10.1097/TP.0000000000000584.
|
[5] |
SaBTO (The Advisory Committee on the Safety of Blood, Tissues and Organs). Transplantation of organs from deceased donors with cancer or a history of cancer[EB/OL]. (2014-04-01). https://www.odt.nhs.uk/transplantation/tools-policies-and-guidance/sabto/.
|
[6] |
European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO) EDQM[M].移植器官质量与安全指南(原书第6版).张雷, 译.北京: 科学出版社, 2019.
|
[7] |
ECCHER A, CIMA L, CIANGHEROTTI A, et al. Rapid screening for malignancy in organ donors: 15-year experience with the Verona "Alert" protocol and review of the literature[J]. Clin Transplant, 2017, 31(9). DOI: 10.1111/ctr.13045.
|
[8] |
KALIKI S, SHIELDS CL. Uveal melanoma: relatively rare but deadly cancer[J]. Eye (Lond), 2017, 31(2):241-257. DOI: 10.1038/eye.2016.275.
|
[9] |
ECCHER A, LOMBARDINI L, GIROLAMI I, et al. How safe are organs from deceased donors with neoplasia? the results of the Italian Transplantation Network[J]. J Nephrol, 2019, 32(2): 323-330. DOI: 10.1007/s40620-018-00573-z.
|
[10] |
VAN ERP AC, VAN DULLEMEN LFA, PLOEG RJ, et al. Systematic review on the treatment of deceased organ donors[J]. Transplant Rev (Orlando), 2018, 32(4):194-206. DOI: 10.1016/j.trre.2018.06.001.
|
[11] |
MILLER AK, YOUNG JW, WILSON DJ, et al. Transmission of donor-derived breast carcinoma as a recurrent mass in a keratolimbal allograft[J]. Cornea, 2017, 36(6):736-739. DOI: 10.1097/ICO. 0000000000001185.
|
[12] |
XIAO D, CRAIG JC, CHAPMAN JR, et al. Donor cancer transmission in kidney transplantation: a systematic review[J]. Am J Transplant, 2013, 13(10): 2645-2652. DOI: 10.1111/ajt.12430.
|
[13] |
WILLIAMS T, ALJITAWI OS, MOUSSA R, et al. First case of donor transmitted non-leukemic promyelocytic sarcoma[J]. Leuk Lymphoma, 2012, 53(12): 2530-2534. DOI: 10.3109/10428194.2012.695360.
|
[14] |
XIE L, ZHOU F. Development of lymphoma from the donor of haploidentical stem cell transplantation: a case report[J]. Mol Clin Oncol, 2017, 7(5): 851-854. DOI: 10.3892/mco.2017.1414.
|
[15] |
DZIEWANOWSKI K, DROZD R, PARCZEWSKI, M et al. Multiorgan transplantation from a deceased donor with intravascular diffuse large B-cell lymphoma: transmission of the disease and results of treatment[J]. Clin Transplant, 2014, 28(10):1080-1083. DOI: 10.1111/ctr.12417.
|
[16] |
CASSOL CA, HOD-DVORAI R, HUBBELL C, et al. Donor-derived philadelphia chromosome positive B-cell lymphoblastic leukemia presenting with renal allograft involvement in the first year post-transplant[J]. Am J Transplant, 2019, 19(3):956-957. DOI: 10.1111/ajt.15117.
|
[17] |
TOFFALORI C, ZITO L, GAMBACORTA V, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation [J]. Nat Med, 2019, 25(4):603-611. DOI: 10.1038/s41591-019-0400-z.
|
[18] |
SOSIN M, NASSIF SR, GIRLANDA R, et al. Isolated peritoneal donor-related plasmacytoma 3 years after liver transplantation: a case report[J]. Am J Transplant, 2014, 14(2):472-476. DOI: 10.1111/ajt.12555.
|
[19] |
ARBER DA, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405. DOI: 10.1182/blood-2016-03-643544.
|
[20] |
GRINFELD J, NANGALIA J, BAXTER EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med, 2018, 379(15): 1416-1430. DOI: 10.1056/NEJMoa1716614.
|
[21] |
BARBUI T, BAROSI G, BIRGEGARD G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet[J]. J Clin Oncol, 2011, 29(6):761-770. DOI: 10.1200/JCO.2010.31.8436.
|
[22] |
WATSON C, ROBERTS R, WRIGHT K, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? an analysis of UK registry data[J]. Am J Transplant, 2010, 10(6): 1437-1444. DOI: 10.1111/j.1600-6143.2010.03130.x.
|
[23] |
ZHAO P, STROHL A, GONZALEZ C, et al. Donor transmission of pineoblastoma in a two‐yr‐old male recipient of a multivisceral transplant: a case report[J]. Pediatr Transplant, 2012, 16(4): E110-E114. DOI: 10.1111/j.1399-3046.2010.01463.x.
|
[24] |
CAVALIERE R, SCHIFF D. Donor transmission of primary brain tumors: a neurooncologic perspective[J]. Transpl Rev, 2004, 18(4): 204-213. DOI: 10.1016/j.trre.2004.09.003.
|
[25] |
HYNES CF, RAMAKRISHNAN K, ALFARES FA, et al. Risk of tumor transmission after thoracic allograft transplantation from adult donors with central nervous system neoplasm—a UNOS database study[J]. Clin Transplant, 2017, 31(4). DOI: 10.1111/ctr.12919.
|
[26] |
LOUIS DN, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6):803-820. DOI: 10.1007/s00401-016-1545-1.
|